Bristol-Myers Squibb Company PFD CONV 2 BMYMP OTC

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) has shown moderate revenue growth over the past 3 years, expanding from $46.2B to $48.2B (average +1.5%/yr). Net income reached $7.1B, reflecting earnings decline at -1.9%/yr on average. The net profit margin is 14.6%, which is moderate. the company was profitable in 3 out of the last 4 years tracked. The gross margin is 67.6% (high), with a -10.4pp trend over the period. With a market cap data available and MOAT composite score of 51/100, the company has a moderate competitive position.

Criteria proven by this page:

• GROWTH (30/100, Partial) — growth is present but not consistently above 5% across both metrics
• PAST (75/100, Partial) — profitability has been inconsistent. Looking at the full 39-year history, the company was profitable in 37 of 39 years — an excellent long-term track record
• INCOME (55/100, Partial) — the company is profitable but margin is below 15%
• MOAT (51/100, Partial) — some competitive advantages are present but not dominant

Overall SharesGrow Score: 45/100 with 0/7 criteria passed.